Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
2期
已完成
NCT03472586
| 适应症 | Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7 |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 14 人 |
|---|
| 干预（药物） | Ipilimumab, Nivolumab, Embolization Therapy |
|---|
| 开始日期 | 2018年5月2日 |
|---|
| 完成日期 | 2022年12月31日 |
|---|
| 结果公布日 | 2023年11月29日 |
|---|
摘要
This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunoembolization may kill tumor cells due to loss of blood supply and develop an immune response against tumor cells. Giving ipilimumab and nivolumab with immunoembolization may work better in treating patients with uveal melanoma.
Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1)
At the end of 4th treatment cycle (Day 84 +/- 3 days). Cycles are 21 days. · Participants
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 0 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 0 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 8 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 5 Participants |
|---|
| Treatment (Ipilimumab, Nivolumab, Immunoembolization) | 1 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。